Actively Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Led by Ascentage Pharma Group Inc. · Updated on 2026-03-27
75
Participants Needed
11
Research Sites
309 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.
CONDITIONS
Official Title
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pathologically confirmed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with measurable lesions or splenomegaly
- Expected survival of at least 12 weeks
- Refractory, recurrent, or intolerant to BTK inhibitors and immunochemotherapy, or first-line BTK inhibitor treatment failure and not suitable for immunochemotherapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- Ability to understand and willingness to sign informed consent
- Willingness and ability to comply with study procedures and follow-up
You will not qualify if you...
- History of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy, or autologous hematopoietic stem cell transplantation within 24 months
- Incomplete recovery from prior surgery; major surgery within 28 days or minor surgery within 14 days before study entry
- Prior treatment with Bcl-2 inhibitors
- Invasive non-Hodgkin lymphoma transformation or central nervous system involvement
- Pregnancy, lactation, or pregnancy expected during the study or within 3 months after last treatment
- History of active malignant tumors other than CLL/SLL within 2 years, except fully treated cervical carcinoma in situ or fully resected basal cell or localized squamous cell skin carcinoma
- Any other condition that investigators consider makes participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
2
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510280
Not Yet Recruiting
3
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
4
Hainan General Hospital
Haikou, Hainan, China, 570311
Not Yet Recruiting
5
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
6
Union Hospital medical college Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
7
The First Affilated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Not Yet Recruiting
8
People's hospital of Jiangsu Province
Suzhou, Jiangsu, China
Not Yet Recruiting
9
The First Affilated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Not Yet Recruiting
10
Institute of blood transfusion of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China, 215127
Not Yet Recruiting
11
The First Affiliated Hospital of Zhejiang University School of Medicine
Hanzhou, Zhejiang, China, 310003
Not Yet Recruiting
Research Team
Z
Zi Chen, Doctor
CONTACT
M
Min Yu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here